Q: Your comments on their last quarter results. Thanks .... Cal
5i Research Answer:
For the third quarter, RX beat EPS estimates of 14c coming in at 20c and was flat year-over-year. Revenue of $9.56M also beat estimates of $9M and displayed growth of 7.7%. EBITDA was $2.85M, declining 2%. RX made an acquisition in the quarter which is expected to contribute to revenue and EBITDA in Q1 of 2025. RX repurchased 162,300 shares in the quarter and management noted, "all of the Company’s Canadian pharmaceutical products contributed to this growth during the quarter." While we do not like to see the slight decline in EBITDA we think these were decent results. RX has done well year-to-date and is trading at 15x forward earnings. We continue to like it as a small cap Canadian healthcare name.